Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a concerning financial performance with a widening net loss and increased expenses due to commercialization activities. The Q&A highlighted uncertainties about payer coverage and formulary approvals, which are crucial for future sales. While there is positive physician feedback, the limited current coverage and the lack of detailed guidance on key metrics contribute to a negative outlook. The stock is likely to react negatively in the short term due to these uncertainties and financial pressures.
Key Financial Performance
Net Product Revenues $0.4 million in the third quarter of 2025, driven by the launch of ORLYNVAH in August 2025, including initial stocking at specialty pharmacies.
Total Operating Expenses $8.1 million in Q3 2025, up from $4.9 million in Q3 2024, a 65% increase year-over-year. The increase was primarily due to commercialization activities for ORLYNVAH.
Cost of Sales $0.02 million in Q3 2025, primarily consisting of royalty payments to Pfizer. Prior to FDA approval in October 2024, manufacturing costs were recorded as R&D expenses.
Amortization of Intangible Assets $0.3 million in Q3 2025, related to regulatory milestone payments to Pfizer upon FDA approval of ORLYNVAH.
Research and Development (R&D) Costs $1.3 million in Q3 2025, down from $3.1 million in Q3 2024, a 58% decrease year-over-year. The decrease was due to lower chemistry manufacturing and control (CMC)-related expenses.
Selling, General, and Administrative (SG&A) Costs $6.5 million in Q3 2025, up from $1.8 million in Q3 2024, a 261% increase year-over-year. The increase was driven by commercialization activities for ORLYNVAH.
Net Loss (GAAP) $9 million in Q3 2025, compared to $6.1 million in Q3 2024, a 48% increase year-over-year. The increase was primarily due to commercialization activities for ORLYNVAH.
Net Loss (Non-GAAP) $7.3 million in Q3 2025, compared to $4.8 million in Q3 2024, a 52% increase year-over-year. The increase was primarily due to commercialization activities for ORLYNVAH, partially offset by lower CMC-related expenses.
Cash and Cash Equivalents $11 million as of the end of September 2025. Combined with $2.6 million raised through an at-the-market offering program, the funds are expected to support operations into Q2 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ORLYNVAH Launch: ORLYNVAH was launched in the U.S. market on August 20, 2025. Over 280 prescriptions have been generated by more than 100 unique prescribers, with nearly half prescribing to multiple patients. Approximately 40% of prescriptions have been filled through payer approval processes.
Specialty Distribution: ORLYNVAH is now available through specialty distributors McKesson and Syncora to accommodate physicians' practice models.
Physician Feedback: Physicians value ORLYNVAH as an alternative for treating uncomplicated urinary tract infections, especially where resistance is a challenge. It helps keep patients out of hospitals and provides a new oral treatment option.
Market Access: Coverage discussions with pharmacy benefit managers and health plans are advancing. A rebate agreement with a top 3 Medicare Part D pharmacy benefit manager has been signed, enabling coverage starting in 2026 or 2027. ORLYNVAH currently reaches 16% of insured lives.
Geographic Expansion: Iterum plans to expand into high-value territories and increase resources in existing geographies, contingent on raising additional capital.
Sales Force Optimization: The in-person field team was reduced from 20 to 10 representatives, supplemented by virtual sales representatives to maintain coverage in 20 target geographies with greater efficiency.
Financial Performance: Net product sales for Q3 2025 were $400,000. Operating expenses for 2026 are estimated at $25-$30 million, with cash runway into Q2 2026. Additional capital is required to sustain operations.
Patent Expansion: New patents were granted in China and Mexico, covering specific formulations and methods, with expirations in 2041 and 2039, respectively.
Capital Raising: Iterum plans to seek shareholder approval to issue additional shares to raise capital for continued commercialization and expansion efforts.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Commercialization Challenges: The company faces challenges in changing long-standing prescribing habits among healthcare providers, which requires frequent office visits and consistent messaging. Additionally, the modest commercial infrastructure limits the ability to scale operations effectively.
Payer Coverage and Reimbursement: A significant portion of prescriptions (60%) are not yet covered by payers, leading to delays in patient access and potential financial barriers. The company is still in the process of securing broader payer coverage, including Medicare plans, which is critical for long-term success.
Financial Sustainability: The company has limited cash reserves, sufficient only until Q2 2026, and has yet to secure additional funding. This creates uncertainty around the ability to sustain operations and continue commercialization efforts.
Market Penetration: Despite initial progress, the company has only reached 16% of insured lives, indicating limited market penetration. This could hinder revenue growth and broader adoption of ORLYNVAH.
Operational Efficiency: The reduction of the in-person field team from 20 to 10 representatives and reliance on virtual sales representatives may impact the effectiveness of sales efforts in key geographies.
Regulatory and Competitive Risks: The company is dependent on ongoing patent protections and faces potential competition from other antibiotic treatments, which could impact market share and revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Net Product Sales: Expected to be in the range of $5 million to $15 million, driven by the commercialization of ORLYNVAH in the U.S. and expansion into new territories.
Operating Expenses for 2026: Estimated to be between $25 million and $30 million for the full year.
Cash Resources: Current cash and cash equivalents are expected to fund operations into Q2 of 2026. Additional capital will be required to continue commercialization efforts throughout 2026.
Capital Raising Plans: Plans to raise additional capital through shareholder approval for issuing more shares or exploring non-dilutive funding options.
Market Access and Payer Coverage: Positive feedback from pharmacy benefit managers and health plans. Signed rebate agreement with a top 3 Medicare Part D pharmacy benefit manager for coverage starting in 2026 or 2027. Coverage currently reaches 16% of insured lives, with expectations for further decisions in upcoming quarters.
Expansion Plans: Plans to expand into high-value territories and increase resources in existing geographies if additional capital is raised.
Patent Protection: New patents granted in China and Mexico, with expirations in 2041 and 2039 respectively, covering specific formulations and methods for ORLYNVAH.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Will the company report specific numbers around patients, prescribers, reps, and coverage for the first few quarters of the launch?
A:Yes, the company plans to report prescriptions, growth, and the number of physicians in the first few quarters. Over time, they may provide less granular data as the launch progresses.
Q:What is the current plan for the number of physician details and sales regions?
A:The company initially planned for 20 territories with high-value targets. With organizational changes and supplemental resources, they aim to effectively cover at least 20 territories, possibly more.
Q:Can you provide more details about the drivers for next year's net sales guidance, particularly payer coverage and physician feedback?
A:Payer coverage is currently at 16% of insured lives. Feedback from physicians has been positive, with interest in keeping high-risk patients out of hospitals and treating recurrent infections effectively. The company is working to get on more formularies to improve efficiency.
Q:When does the company expect formulary approvals from PBMs?
A:The company hopes to secure formulary approvals by the end of this quarter or the first quarter of next year. They have submitted bids to the three big PBMs and major Medicare Part D plans.
Q:Is there a strategy to use advertising or social media to drive uptake for ORLYNVAH?
A:Currently, the focus is on field organization and supporting materials. However, the company is considering optimizing its social media presence in the future.
Q:Will the company release information on the types of patients being treated, such as high-risk or specific comorbidities?
A:The company will not have detailed specifics due to confidentiality but will gather anecdotal information from prescribing physicians to optimize their approach.
Q:Is there interest in using ORLYNVAH for infections beyond its approved indication?
A:Yes, there is inbound interest from physicians outside the company's call list. While the company will only promote the approved indication, they will respond to physician inquiries and supply the product as needed.
Q:What is the plan for augmenting the sales team with virtual efforts?
A:The company plans to use a combination of in-field and virtual reps to cover at least 28 territories effectively. Virtual reps are seen as efficient due to their ability to schedule meetings and avoid travel time.
Q:Are other marketing channels like medical journals or social media being considered?
A:Yes, the company is considering social media as it is more effective than traditional journal ads. They will evaluate the return on investment for these channels and prioritize based on available capital.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for physician details and territories, citing confidentiality. They also did not commit to releasing detailed patient data, citing doctor-patient confidentiality. Additionally, while they acknowledged interest in using ORLYNVAH for broader infections, they avoided discussing any plans to expand its approved indication.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Commercial
Commercial Officer
Medicare
ORLYNVAH commercialization
ORLYNVAH patient
ORLYNVAH physician
ORLYNVAH promotion
ability
access coverage
adoption
behavior
benefit manager
capital
care provider
cash
coverage ORLYNVAH
date
decision
disease
experience ORLYNVAH
feedback
field
formulary
health care
launch
number
payer
pharmacy benefit
prescribers
prescription
progress
resource
sale
specialty pharmacy
territory
update
way
week
ITRM Transcript
Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call reveals a concerning financial performance with a widening net loss and increased expenses due to commercialization activities. The Q&A highlighted uncertainties about payer coverage and formulary approvals, which are crucial for future sales. While there is positive physician feedback, the limited current coverage and the lack of detailed guidance on key metrics contribute to a negative outlook. The stock is likely to react negatively in the short term due to these uncertainties and financial pressures.
Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call presents a mixed picture. Financial performance shows improvement with reduced losses and operating expenses, which is positive. However, the lack of clarity on partnerships and the need for capital raising post-launch are concerning. The absence of a share repurchase program and competition risks further dampen sentiment. Despite projected sales potential, uncertainties in commercialization plans and strategic alternatives evaluation create a balanced outlook, suggesting a neutral stock price movement in the short term.
Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges
Unknown2-7
The earnings call highlights significant risks, including going concern issues, capital raising challenges, and uncertainties about market acceptance. Despite reduced operating expenses and net losses, the company's financial health remains precarious due to a deferred $20 million payment to Pfizer accruing interest. The lack of clear guidance on strategic partnerships further exacerbates concerns. The Q&A section reveals management's evasiveness, which may increase investor apprehension. Given these factors, the stock price is likely to face a negative reaction over the next two weeks.
Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript
Unknown11-14
The earnings call presents a mixed outlook. Financial performance shows reduced operating expenses and net loss, but there's a significant cash flow risk due to outstanding exchangeable notes and deferred milestone payments. The Q&A reveals strategic uncertainties and limited clarity on future partnerships. The lack of European patents and the need for additional studies in key markets like China and Japan further complicate the outlook. Despite a promising label for ORLYNVAH, these factors balance out, suggesting a neutral stock price movement over the next two weeks.
ITRM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
